South Africa to host third global forum on TB vaccines

NewsGuard 100/100 Score

"This week more than 250 scientists, researchers, and tuberculosis (TB) advocates from all over the world will gather in Cape Town, South Africa, at the Third Global Forum on TB Vaccines to share findings and look to the future of TB vaccine research and development," Tom Evans, CEO of Aeras, and Jelle Thole, founder and director of the Tuberculosis Vaccine Initiative (TBVI), write in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, noting it is the first time the forum will be held on the African continent. "The South African Tuberculosis Vaccine Initiative (SATVI) is playing host to the global gathering at the University of Cape Town," they continue, adding, "South Africa is in a unique position as an emerging economy at the cutting edge of innovation and scientific research coupled with a devastating TB epidemic, in which TB incidence has increased by 400 percent over the past 15 years, and where control is hampered by HIV co-infection and a rising number of patients affected with MDR strains" (3/26).

Print This ArticlePrint Entire Report


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows potential for universal flu vaccine with broad antibody response